Nexalin Technology shares are trading higher after the company announced the launch of its Gen-3 Halo Headset clinical trial for at-home mTBI treatment through a partnership with UC San Diego and San Diego VA.
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology's shares rose following the announcement of a clinical trial for its Gen-3 Halo Headset, aimed at treating mild traumatic brain injury (mTBI) at home. The trial is in partnership with UC San Diego and San Diego VA.
October 22, 2024 | 7:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology's stock is up due to the launch of a clinical trial for its Gen-3 Halo Headset, which could enhance its market position in mTBI treatment.
The announcement of a clinical trial for a new product, especially in partnership with reputable institutions like UC San Diego and San Diego VA, is likely to boost investor confidence and drive up the stock price. This development positions Nexalin Technology as a key player in the mTBI treatment market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100